Kiniksa Pharmaceuticals International price to book ratio KNSA

Market value divided by the book value of the company's net assets, since 2018.

Today, Oct 23, 2026: 9.2×
8-year median: 3.6×
Against its 8-year history: 98th; percentile: 0 is its lowest day, 100 its highest
8-year range: 1.0× to 9.5×
Peer median: 13.2×

Kiniksa Pharmaceuticals International's price to book ratio is 9.2× as of Oct 23, 2026.

That is above its 8-year median of 3.6×, higher than on 98% of days in the last 8 years.

Over that time it ranged from 1.0× in Oct 2019 to 9.5× in Oct 2026.

The median for 10 large drugmakers of a similar size is 13.2×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	9.2×	5.6×	9.5×
2025	5.9×	3.1×	6.1×
2024	3.3×	2.7×	4.5×
2023	3.0×	1.9×	3.4×
2022	2.7×	2.5×	6.3×
2021	3.8×	3.0×	5.1×
2020	3.4×	2.7×	6.6×
2019	2.5×	1.0×	4.0×
2018	3.9×	2.0×	4.3×

Against its peers

Companies in Drug Manufacturers - General nearest Kiniksa Pharmaceuticals International's size, closest first, today.

Company	Price to book ratio
KNSAKiniksa Pharmaceuticals International	9.2×
LGNDLigand Pharmaceuticals	6.3×
AMRXAmneal Pharmaceuticals	197×
ALKSAlkermes plc.	4.0×
TGTXTG Therapeutics	13.7×
INDVIndivior Pharmaceuticals	n/m
PTGXProtagonist Therapeutics	10.6×
ARQTArcutis Biotherapeutics	17.8×
CORTCorcept Therapeutics	13.2×
LQDALiquidia	19.6×
OGNOrganon	3.6×
Peer median	13.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Kiniksa Pharmaceuticals International

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.